Skip to content

Vera Therapeutics VERA Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Immunome logo
ImmunomeIMNM
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
Immunovant, Inc. logo
Immunovant, Inc.IMVT
TG Therapeutics logo
TG TherapeuticsTGTX
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's operating lease right-of-use asset amortization?
Vera Therapeutics (VERA) reported operating lease right-of-use asset amortization of $116K in Q1 2026.
How has Vera Therapeutics's operating lease right-of-use asset amortization changed year-over-year?
Vera Therapeutics's operating lease right-of-use asset amortization decreased by 74.6% year-over-year, from $457K to $116K.